KYTECBIO develops albumin-binding technologies for targeted drug delivery and diagnostics, specifically focusing on peptide, molecular, and protein therapeutics. Their platform enhances the precision of cancer treatments and improves diagnostic accuracy, addressing the challenges of effective drug administration and disease detection.
Funding
Funding not disclosed
Founders
Product
Problem
Effective drug delivery and accurate diagnostics are hampered by the challenges of targeting therapeutics and detecting diseases with precision, especially in cancer treatment. Traditional methods often lack the specificity needed to minimize off-target effects and improve diagnostic accuracy.
Solution
KYTECBIO develops albumin-binding technologies to enhance targeted drug delivery and diagnostics. Their FLIC™ platform leverages albumin's natural affinity to bind with peptide, molecular, and protein therapeutics, improving the precision of cancer treatments and other applications. By creating "bioorthogonal click fluorescent probes" that react rapidly with albumin, the platform simplifies linker structures compared to antibody-drug conjugates. KYTECBIO is also developing diagnostic kits for detecting urinary protein and serum albumin using FLIC™ technology and holds international patents for cell and protein imaging applications.
Target Audience
KYTECBIO's primary customers include pharmaceutical companies, diagnostic kit manufacturers, and research institutions focused on developing targeted therapies and advanced diagnostic tools.
Features
- FLIC™ (Fluorescent Ligand Interaction Chemistry) platform for albumin-based diagnostics and drug delivery.
- Bioorthogonal click fluorescent probes that selectively react with albumin.
- Technology for producing non-natural amino acids via an automated flow process using ARCA materials.
- Real-time cell imaging probes that react with specific substances within cells to visualize them.
- Development of diagnostic kits for detecting urinary protein and serum albumin.
- Holds patents for cell imaging and protein imaging.
- Technology for photodynamic therapy (PDT) with enhanced cancer cell targeting capabilities.